Immune Response BioPharma Sets Pricing of REMUNE Vaccine in Thailand Between $75 -100 Per Dose

Published: May 20, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRLog (Press Release) - May 19, 2013 - NEW YORK -- Immune Response BioPharma, Inc. Sets Pricing of REMUNE Vaccine in Thailand in the range of Between $75-100 Per Dose for Emergency Approval of HIV/AIDS Vaccine.

Immune Respone BioPharma, Inc. Today Announces it's pricing policy for REMUNE in the initial range between $75-100 per dose for the poor and indigent in Thailand, IRBP will seek emergency approval of REMUNE in Thailand as well begin stockpiling & manufacturing the HIV/AIDS vaccine once we have an agreement in place with the Thailand officials and partners in the region.

IRBP intends to get the price of the REMUNE HIV/AIDS Vaccine as low as possible for the poor and indigent in Thailand. If IRBP is successful in negotiating lower prices with our vendors we will pass it along to patients in Thailand suffering from this debilitating disease. Initial manufacturing and commercialization costs will be high and costly to manufacture clinical grade REMUNE on a bulk level. IRBP believes once it builds its own plant the cost for the vaccine will come down dramatically. IRBP estimates 9-12 months of lead time before the first batch of REMUNE is commercially available upon successful registration in Thailand and an agreement is in place with Thailand officials and partners.

Overseas Countries interested in licensing REMUNE from Immune Response BioPharma, Inc. should contact us @ or Dr. Jeffrey Taylor of NW Clinical Research @

REMUNE is a therapeutic vaccine designed to elicit immune responses against a variety of HIV antigens in patients with HIV. It consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund’s Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil).

REMUNE® is derived from Zairian HIV-1 strain HZ-321, composed of gp 120-depleted HIV-1 propagated in HUT-78 cells and inactivated in beta-propiolactone and irradiation. The inactivated material is emulsified with mineral oil (Incomplete Freund's Adjuvant) at 1:1 ratio. Each 1 ml dose (at least 100µg or 10 units) has viral protein and p24.


These previous clinical studies of REMUNE®have demonstrated distinct benefits in both immunologic and virologic parameters in HIV-1 infected individuals undergoing treatment. Subjects undergoing treatment with REMUNE®showed improvements in percentage of CD4 cells, HIV-1 DNA in PBMCs, and weight. Previous studies also indicate that REMUNE®can safely be given in combination with antiviral drugs.

IR103/Remune,unlike antiviral drugs, can induce an HIV-specific response, which is now thought by numerous researchers to be important in controlling HIV replication. Remune has been administered to over 2,000 patients in over 25 separate clinical trials, has an excellent safety profile, is well tolerated and is easy to administer via intramuscular injection in the deltoid muscle.

Data from clinical trials of Remune suggest that it may:

Induce a HIV-specific T-cell response; work in Patients with Multi-Drug Resistance

Induce cytokines and chemokines, substances that interfere with the virus attaching to and infecting normal cells;

Work with antiretroviral drugs as a complementary treatment for HIV infection;

Work in drug-naïve patients to delay the need for initiation of HAART; and

Be safe with no adverse side effects, Reduce Viral Load, Increase CD4+ T cells & CD8+ T Cell Counts

Immune Response BioPharma, Inc. Maybe Found on the World Wide Web @

Help employers find you! Check out all the jobs and post your resume.

Back to news